Should I Buy BIVI? BIVI 2026 Analysis

Should You Buy BioVie Inc (BIVI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.240

1 Day change

0.81%

52 Week Range

20.400

Analysis Updated At

2026/01/28

BIVI is not a good buy right now for a Beginner, long-term investor with $50,000–$100,000 who is impatient and doesn’t want to wait for an ideal entry. The stock is in a broader downtrend (bearish moving averages), the company has no revenue and continues to post sizable losses, and there are no near-term news catalysts or strong proprietary buy signals to justify stepping in today. **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock today.

Technical Analysis

Price is around $1.20 with key levels: Pivot 1.218, Support S1 1.157 (then S2 1.119), Resistance R1 1.279 (then R2 1.317). Trend is technically bearish because SMA_200 > SMA_20 > SMA_5 (downtrend structure). However, MACD histogram is positive (0.00644) and expanding, suggesting a short-term attempt to stabilize or bounce. RSI(6) at ~42 is neutral-to-weak, not showing strong momentum. Net: the dominant trend remains bearish, and a convincing breakout would require reclaiming/holding above the 1.218–1.279 area; losing 1.157 increases downside risk.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options data is effectively thin/limited (many fields blank), with very high historical volatility (~98.53), which typically reflects elevated uncertainty and speculative pricing. The displayed put-call ratios at 0.0 likely reflect data sparsity rather than a strong bullish consensus. Overall, options do not provide a reliable bullish sentiment confirmation here.

Technical Summary

Sell

Buy

Positive Catalysts

- MACD turning positive/expanding hints at a potential short-term stabilization attempt.
- No heavy hedge fund/insider selling trend flagged recently (both noted as neutral).
- Pre-market was modestly positive (+1.65%), though not a decisive signal.

Neutral/Negative Catalysts

- No news in the recent week: no obvious event-driven catalyst to change the narrative.
- Clear bearish moving-average stack (SMA_200 > SMA_20 > SMA_5) indicates the broader trend is still down.
- Extremely high volatility profile (historical vol ~98.5%) makes this a poor fit for a beginner long-term allocation.
- Company fundamentals show no revenue and ongoing losses, keeping financing/dilution risk in focus for small biotechs.
- No recent congress trading data; no “influential buyer” confirmation from that channel.

Financial Performance

Latest reported quarter: 2026/Q1. Revenue was 0 (no growth base), indicating the company is still pre-commercial. Net income improved YoY to -$5.13M (loss narrowed ~14.61% YoY), but EPS fell to -0.98 (down ~86% YoY), which is a meaningful deterioration on a per-share basis. Overall: still loss-making with no revenue traction, not showing the kind of durable growth profile that supports a comfortable long-term beginner buy today.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there’s no clear recent Wall Street upgrade/downgrade trend to lean on. With the available information (no revenue, continuing losses, and a bearish technical structure), the implied ‘pros vs cons’ view skews negative: pros are limited to speculative upside and short-term technical stabilization; cons are weak trend, lack of catalysts, and poor visibility on business fundamentals.

Analyst Rating

Wall Street analysts forecast BIVI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIVI is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 1.230

Low

Averages

High

Current: 1.230

Low

Averages

High

Brookline

NULL -> Buy

maintain

$6 -> $12

AI Analysis

2025-08-29

Reason